GlassScriptPhysician profile
Gregory L Fuqua
NPI 1245298306
$8,111.38
in general payments reported to CMS, 2019-2025
45 companies · $51.07 in 2025
The $51.07 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,388 · 2020: $1,065 · 2021: $230 · 2022: $1,918 · 2023: $1,614 · 2024: $846 · 2025: $51.07.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,461 · Education: $50.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,460.91 |
| Education | $50.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,496.57 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $729.50 | 2019-2024 | Mounjaro, Jardiance, Emgality |
| Astrazeneca Pharmaceuticals LP | $688.81 | 2019-2024 | Farxiga, Airsupra |
| Pfizer INC. | $686.51 | 2019-2024 | |
| Glaxosmithkline, LLC. | $613.27 | 2019-2025 | Trelegy Ellipta, Blenrep, Shingrix |
| Abbvie INC. | $449.32 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $367.94 | 2019-2024 | Jardiance, Synjardy, Tradjenta |
| Novartis Pharmaceuticals Corporation | $269.14 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $239.88 | 2019-2022 | |
| Amgen INC. | $233.39 | 2019-2023 | Otezla, Repatha, Prolia |
| Otsuka America Pharmaceutical, INC. | $221.16 | 2022-2023 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $191.04 | 2019-2024 | Austedo Xr |
| Amarin Pharma, INC. | $190.04 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $189.75 | 2019-2023 | Xifaxan |
| Janssen Pharmaceuticals, INC | $180.26 | 2019-2023 | Spravato |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Fuqua listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.